Federal Register Notice: FDA’s Anti-Infective Drugs Advisory Committee will meet 2/27-28, from 8 a.m. to 5 p.m. at the Crowne Plaza Silver Spring, The Ballrooms, 8777 Georgia Ave., Silver Spring, MD. Contact Sohail Mosaddegh, (301) 827-7001. On 2/27 the committee will discuss Theravance, Inc.’s NDA for telavancin powder for reconstitution and intravenous administration, proposed for treating complicated skin and skin structure infection. On 2/28, the committee will discuss Johnson and Johnson Pharmaceutical’s NDA for ceftobiprole medocaril (500 mg), lyophilized powder for reconstitution and intravenous administration, for treating complicated skin and skin structure infection. To view this notice, click here.